Product Details

Uniprot No.

Target Names

Alternative Names

c-Jun N-terminal kinase kinase 2 antibody; Dual specificity mitogen activated protein kinase kinase 7 antibody; Dual specificity mitogen-activated protein kinase kinase 7 antibody; JNK activating kinase 2 antibody; JNK kinase 2 antibody; JNK-activating kinase 2 antibody; JNKK 2 antibody; Jnkk-2 antibody; Jnkk2 antibody; MAP kinase kinase 7 antibody; MAP2K7 antibody; MAPK/ERK kinase 7 antibody; MAPKK 7 antibody; MAPKK-7 antibody; MAPKK7 antibody; MEK 7 antibody; Mitogen Activated Protein Kinase kinase 7 antibody; MKK 7 antibody; MKK-7 antibody; MKK7 antibody; MP2K7_HUMAN antibody; PRKMK 7 antibody; PRKMK-7 antibody; PRKMK7 antibody; SAPK kinase 4 antibody; SAPKK-4 antibody; SAPKK4 antibody; Sek 2 antibody; Sek-2 antibody; Sek2 antibody; SKK4 antibody; stress-activated protein kinase kinase 4 antibody

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human MAP2K7

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

2C2

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, WB, IF, FC

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
IF	1:50-1:200
FC	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

MAP2K7, also known as MKK7, serves as a critical upstream activator in the JNK signaling cascade, where it functions as a dual-specificity kinase that phosphorylates and activates c-Jun N-terminal kinases. This pathway plays essential roles in cellular stress responses, apoptosis, and inflammatory signaling, making MAP2K7 a key target for researchers investigating cancer biology, immune regulation, and neurodegenerative disease mechanisms.

This recombinant monoclonal antibody, clone 2C2, offers the reproducibility and consistency that demanding experimental workflows require. Produced using recombinant technology with a defined sequence, it eliminates the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations. The rabbit host and monoclonal format ensure high specificity for human MAP2K7, providing reliable detection across your experiments.

Validation across multiple platforms demonstrates this antibody's versatility in your research toolkit. Western blot analysis confirms robust detection in human cell lines including HEK293T, HeLa, HL-60, Jurkat, and K562, with optimal performance at dilutions between 1:500 and 1:2000. The observed band at approximately 55 kDa, slightly higher than the predicted 47 kDa molecular weight, likely reflects post-translational modifications such as phosphorylation events characteristic of this active kinase. Immunofluorescence studies in HepG2 cells reveal clear cytoplasmic localization patterns, while flow cytometry validation in A549 cells demonstrates distinct positive population shifts compared to isotype controls.

Whether you are mapping stress-activated signaling networks, characterizing kinase pathway dysregulation in disease models, or screening therapeutic targets affecting JNK activation, this antibody provides the specificity and application flexibility needed to advance your research with confidence.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific role in JNK signal transduction pathway activated by proinflammatory cytokines. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Part of a non-canonical MAPK signaling pathway, composed of the upstream MAP3K12 kinase and downstream MAP kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated transcription of APP in response to APOE.

Gene References into Functions

The assessment of the interaction between GADD45beta and MKK7 and the elucidation of the recognition surfaces between DTP3 and MKK7 significantly advance the understanding of the mechanism underlying the inhibition of the GADD45beta/MKK7 interaction by DTP3 and pave the way to the design of small-molecule DTP3 analogues. PMID: 29572137
In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study PMID: 28444112
the p.Glu116Lys rare variant in MAP2K7 predisposes its carriers to develop COPD, which would provide a useful genetic biomarker for COPD susceptibility in Chinese. PMID: 28120412
Combination BRAF and MEK inhibition has also been shown to improve overall survival in patients with V600E-mutated melanoma. Responses to therapy are often rapid, and treatment is not associated with immune-related adverse events. PMID: 28561662
The latter insight is likely to promote the production of allosteric MAP2K7 inhibitors. PMID: 28890347
MEK activation cooperates with Cdkn2a and Pten inactivation to induce melanoma PMID: 28263969
MKK7 undergoes neddylation in human breast cancer cells PMID: 26364603
In an Eastern Chinese population, carriers of MAP2K7 rs3679T variant genotypes had an increased risk of NSCLC. PMID: 27861856
combined pan-RAF and MEK inhibition can overcome intrinsic and acquired resistance to single-agent RAF/MEK inhibition, supporting dual pan-RAF and MEK inhibition as a novel therapeutic strategy for BRAF- and KRAS-mutant cancers PMID: 26351322
our study suggested that black rice anthocyanins extract suppress metastasis in breast cancer cells by targeting the RAS/RAF/MAPK pathway PMID: 26649302
Crystal structures of the wild type and C218S mutant of MAP2K7 were determined. Cys218 plays a crucial role in configuring an auto-inhibition form of MAP2K7. PMID: 26987717
We found that the MKK7 p.Glu116Lys rare polymorphism was significantly associated with lung cancer risk, progression and prognosis PMID: 27028764
we explored the effects of selumetinib in combination with gefitinib in a panel of TNBC cells, in order to evaluate whether the simultaneous blockade of the EGFR and the RAS/MEK/ERK pathway might increase the antitumor activity of selumetinib in TNBC. PMID: 25959272
a widespread role for the JNK-CELF2 axis in controlling splicing during T-cell activation, including a specific role in propagating JNK signaling. PMID: 26443849
This review will focus on the science and clinical findings related to targeted therapies that inhibit BRAF or MEK as well as the immunotherapies that block the CTLA-4 or PD-1 pathways PMID: 25899612
BCR-ABL promotes PTEN downregulation through a MEK dependent pathway. PMID: 25343485
In conclusion, the expression of hepatitis B virus core protein sensitized hepatocytes to TNF-alpha-induced apoptosis by disrupting the interaction between MKK7 and RACK1. PMID: 25428880
Combination of AAG8 antagonist and very low concentration of a MEK inhibitor synergistically restricts the growth of drug-resistant cells. PMID: 24634165
MKK7 is a major functional target of miR-493, and its suppression thwarts liver metastasis of colon cancer cells. PMID: 24533778
Gadd45B protects the liver through two entirely different processes: binding MKK7 to block damaging signal transduction or binding CAR to coactivate anabolic transcription. (Review) PMID: 24104474
the results imply that reduced function of the MAP2K7-c-Jun N-terminal kinase (JNK) signalling cascade may underlie some of the neurochemical changes and core symptoms in schizophrenia. PMID: 22899651
Overexpressed RACK1 augments JNK activity and thereby promotes hepatocellular carcinoma growth through directly binding to MKK7 and enhancing MKK7 activity. PMID: 22903704
Taxol induces apoptosis in chronic myelogenous leukemia cells by inducing intracellular oxidative stress and JNK activation pathway. PMID: 21074392
Alpinetin suppresses proliferation of human hepatoma cells by the activation of MKK7 and elevates sensitization to cis-diammined dichloridoplatium. PMID: 22159816
a novel function for the stress kinase MKK7 as a regulator of the circadian clock in mammalian cells at steady state. PMID: 22267733
WDR62 associates directly with the MKK7beta1 isoform independently of JNK binding, but fails to interact with MKK7alpha1. PMID: 21749326
ML-1 activated a MAP kinase and an extracellular signal-regulated kinase (ERK)1/2 but not p38 or the c-Jun N-terminal kinase (JNK) PMID: 11891214
JNK, MKK-4, and MKK-7 form an active signaling complex in rheumatoid arthritis and this novel JNK signalsome is activated in response to IL-1 and migrates to the nucleus. PMID: 13130464
report the cloning of hMKK7gamma1, the human homolog of murine MKK7gamma1 PMID: 16442502
MKK7 contains three JNK-docking sites that interact to selectively bind JNK and contribute to JNK signal transmission and specificity PMID: 16533805
data indicate that only MKK-7 is required for JNK activation in fibroblast-like synoviocytes after cytokine stimulation PMID: 16802349
Association of Gadd45beta with MKK7 involves a network of interactions mediated by its putative helices alpha3 and alpha4 and loops 1 and 2 PMID: 17485467
p38 MAPK inhibitors SB202190 and SB203580 activated JNK via MLK-3/MKK7 pathway. PMID: 18222647
The results suggest the occurrence of a large complex containing at least an MKK7-Gadd45 beta:Gadd45 beta-MKK7 tetrameric unit whose complexity could be further increased by the dimeric nature of the isolated MKK7. PMID: 18343408
Disruption of signaling through MKK7 yields differential response in hypoxic colon cancer cells treated with oxaliplatin. PMID: 18436711

Hide All

Subcellular Location

Nucleus. Cytoplasm.

Protein Families

Protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase subfamily

Tissue Specificity

Ubiquitous; with highest level of expression in skeletal muscle. Isoform 3 is found at low levels in placenta, fetal liver, and skeletal muscle.

Database Links

HGNC: 6847

OMIM: 603014

KEGG: hsa:5609

STRING: 9606.ENSP00000381066

UniGene: Hs.531754

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA563777A0HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in: HEK293T whole cell lysate(20µg),Hela whole cell lysate(20µg), HL-60 whole cell lysate(20µg), Jurkat whole cell lysate(20µg),K562 whole cell lysate(20µg) All lanes: MEK7 antibody at 1:1000 Secondary Goat polyclonal to rabbit IgG at 1/40000 dilution Predicted band size: 47 kDa Observed band size: 55 kDa Exposure time：20s Immunofluorescence staining of HepG2 cell with CSB-RA563777A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L). Overlay Peak curve showing A549 cells stained with CSB-RA563777A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

MAP2K7 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background